Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | SMYD2 | Q9NRG4 | 5/20 | 0.46 |
| ▸ | MKNK2 | Q9HBH9 | 3/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | ULK1 | O75385 | 1/20 | 0.44 |
| ▸ | STAT3 | P40763 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.43 |
| ▸ | KIT | P10721 | 1/20 | 0.43 |
| ▸ | KDR | P35968 | 1/20 | 0.43 |
| ▸ | NAMPT | P43490 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3401280 | 0.94 | RAB9A (0.48) | RAB9AGAASMYD2MKNK2MAPT | |
| SCHEMBL3401313 | 0.94 | SCN9A (0.47) | STAT3PDGFRBKITKDR | |
| SCHEMBL3405360 | 0.93 | SCN9A (0.49) | GAASTAT3PDGFRBKITKDR | |
| SCHEMBL3404848 | 0.91 | RAB9A (0.45) | RAB9AGAASMYD2MKNK2MAPT | |
| SCHEMBL3405409 | 0.88 | SCN9A (0.47) | RAB9ASTAT3PDGFRBKDR | |
| SCHEMBL3401224 | 0.87 | SCN9A (0.49) | RAB9AGAASTAT3 | |
| SCHEMBL3402585 | 0.86 | DRD2 (0.47) | SMYD2MKNK2 | |
| SCHEMBL3400482 | 0.86 | DRD2 (0.46) | GAASMYD2MAPTKMT2A | |
| SCHEMBL3405260 | 0.85 | GAA (0.48) | GAASMYD2MAPTKMT2A | |
| SCHEMBL3402417 | 0.83 | CHRM4 (0.49) | RAB9AGAAMAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100297035-A1 | Thiazole Amides, Imidazole Amides and Related Analogues | LIGAND PHARMACEUTICALS, INC. (US) | 2010-11-25 | — | — | US | disclosed |
| US-7728009-B1 | Thiazole amides, imidazole amides and related analogues | NEUROGEN CORPORATION (US) | 2010-06-01 | — | — | US | disclosed |
| US-7728009-B1 | Thiazole amides, imidazole amides and related analogues | NEUROGEN CORPORATION (US) | 2010-06-01 | — | — | US | disclosed |
| US-7728009-B1 | Thiazole amides, imidazole amides and related analogues | NEUROGEN CORPORATION (US) | 2010-06-01 | — | — | US | disclosed |
| WO-2006089076-A9 | THIAZOLE AMIDES, IMIDAZOLE AMIDES AND RELATED ANALOGUES | NEUROGEN CORP (US) | 2007-04-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100297035-A1 | Thiazole Amides, Imidazole Amides and Related Analogues | HRH3, HRH4, HRH2 | RAB9A 2102/4885GAA 1659/4885SMYD2 3691/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.